SLYMEC II study: Overall survival analysis of the impact of LVSI in apparent early stage endometrioid endometrial cancer
Jessica Mauro(Ospedale San Pietro Fatebenefratelli), Alessandro Buda(Ospedale San Pietro Fatebenefratelli), Sara Imboden(University of Bern), Ignacio Zapardiel(Hospital Universitario La Paz), Giovanni Scambia(Agostino Gemelli University Polyclinic), Enrico Vizza(Human Technopole), Andrea Papadia(University of Bern), Elena De Ponti, Valentina Bruno(University of Rome Tor Vergata), Virginia García-Pineda(Hospital Universitario La Paz), Mete Güngör(Acıbadem University), Vito Andrea Capozzi(University of Parma), Giuseppe Vizzielli(University of Udine), Ilaria Capasso(Università Cattolica del Sacro Cuore), Michael D. Mueller(University of Bern), Jvan Casarin(University of Insubria), Salih Taşkın(Ankara University), Robert Fruscio(Azienda Ospedaliera San Gerardo), Emanuele Perrone(Agostino Gemelli University Polyclinic), Tommaso Grassi(University of Milano-Bicocca), Doğan Vatansever(University Hospital of Bern), Diego Raimondo(Azienda USL di Bologna), Çağatay Taşkıran(Koç University), Franziska Siegenthaler(University Hospital of Bern), Francesco Fanfani(Agostino Gemelli University Polyclinic), Stefano Restaino(University of Udine)
Cited by 5
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres
|Human Reproduction|2012|1.1k